Provided by Tiger Trade Technology Pte. Ltd.

Serina Therapeutics, Inc.

2.00
-0.0100-0.50%
Post-market: 2.000.00000.00%19:30 EDT
Volume:22.35K
Turnover:44.90K
Market Cap:50.80M
PE:-1.04
High:2.05
Open:1.99
Low:1.99
Close:2.01
52wk High:5.60
52wk Low:1.22
Shares:25.40M
Float Shares:11.48M
Volume Ratio:0.92
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9304
EPS(LYR):-1.9100
ROE:-207.94%
ROA:-92.30%
PB:2.71
PE(LYR):-1.05

Loading ...

Jun 10, 2024

Major Issues Report

Form 8-K - Current report
May 14, 2024

Major Issues Report

Form 8-K - Current report
May 14, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 03, 2024

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
May 03, 2024

Major Issues Report

Form 8-K - Current report
Apr 17, 2024

Major Issues Report

Form 8-K - Current report
Apr 03, 2024

Beneficial Ownership Change

Form SC 13D - General statement of acquisition of beneficial ownership
Apr 01, 2024

Major Issues Report

Form 8-K - Current report
Mar 26, 2024

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Mar 22, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 22, 2024

Major Issues Report

Form 8-K - Current report
Mar 14, 2024

Major Issues Report

Form 8-K - Current report
Mar 07, 2024

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Mar 07, 2024

Major Issues Report

Form 8-K - Current report
Mar 07, 2024

Business Combinations

Form 425 - Prospectuses and communications, business combinations
Feb 14, 2024

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Feb 14, 2024

Major Issues Report

Form 8-K - Current report
Feb 13, 2024

Correspondence

Form CORRESP - Correspondence
Feb 06, 2024

Correspondence

Form CORRESP - Correspondence
Jan 19, 2024

Major Issues Report

Form 8-K - Current report